Steward D L, Welge J A, Myer C M
Department of Otolaryngology--Head and Neck Surgery, University of Cincinnati College of Medicine, OH 45267-0528, USA.
Laryngoscope. 2001 Oct;111(10):1712-8. doi: 10.1097/00005537-200110000-00008.
OBJECTIVES/HYPOTHESIS: The study aims to reconcile conflicting published reports regarding the clinical efficacy of a single intraoperative dose of dexamethasone in reducing post-tonsillectomy morbidity.
Systematic overview (meta-analysis).
To critically evaluate the existing evidence, we performed a formal meta-analysis of eight double-blinded, randomized, placebo-controlled studies of dexamethasone in pediatric patients undergoing tonsillectomy or adenotonsillectomy. Reduction in postoperative emesis and pain, as well as early return to soft or solid diet, were studied as distinct end points.
Children being given a single intraoperative dose of dexamethasone (dosing, 0.15-1.0 mg/kg; maximum dose, 8-25 mg) were two times less likely to vomit in the first 24 hours than children being given placebo (relative risk [RR] = 0.55; 95% confidence interval [CI], 0.41-0.74; P < .0001). Routine use in four children would be expected to result in one less patient having post-tonsillectomy emesis (risk difference [RD] = -0.24; 95% CI, -0.38 to -0.10; P = .0006). In addition, children being given dexamethasone were more likely to advance to a soft or solid diet on post-tonsillectomy day 1 (RR = 1.69; 95% CI, 1.02-2.79; P = .04) than those being given placebo. Because of missing data and varied outcome measures, pain could not be meaningfully analyzed as a distinct end point.
Given the frequency of tonsillectomy, relative safety and low cost of dexamethasone, and the reduction in postoperative morbidity, we recommend routine use of a single intravenous dose during pediatric tonsillectomy.
目的/假设:本研究旨在调和已发表的关于术中单次使用地塞米松降低扁桃体切除术后发病率的临床疗效的相互矛盾的报告。
系统综述(荟萃分析)。
为严格评估现有证据,我们对八项关于地塞米松在接受扁桃体切除术或腺样体扁桃体切除术的儿科患者中的双盲、随机、安慰剂对照研究进行了正式的荟萃分析。将术后呕吐和疼痛的减轻以及早期恢复软食或固体食物作为不同的终点进行研究。
术中单次给予地塞米松(剂量为0.15 - 1.0 mg/kg;最大剂量为8 - 25 mg)的儿童在术后24小时内呕吐的可能性比给予安慰剂的儿童低两倍(相对风险[RR]=0.55;95%置信区间[CI],0.41 - 0.74;P <.0001)。预计每4名儿童常规使用地塞米松可使扁桃体切除术后呕吐的患者减少1例(风险差[RD]= - 0.24;95% CI, - 0.38至 - 0.10;P =.0006)。此外,与给予安慰剂的儿童相比,接受地塞米松治疗的儿童在扁桃体切除术后第1天更有可能过渡到软食或固体食物(RR = 1.69;95% CI,1.02 - 2.79;P =.04)。由于数据缺失和结局测量方法不同,疼痛无法作为一个独立的终点进行有意义的分析。
鉴于扁桃体切除术的频率、地塞米松的相对安全性和低成本以及术后发病率的降低,我们建议在儿科扁桃体切除术中常规单次静脉使用地塞米松。